...
首页> 外文期刊>International Journal of Biological Macromolecules: Structure, Function and Interactions >Synthesis and assessment of sodium alginate-modified silk fibroin microspheres as potential hepatic arterial embolization agent
【24h】

Synthesis and assessment of sodium alginate-modified silk fibroin microspheres as potential hepatic arterial embolization agent

机译:藻酸钠改性丝素蛋白微球作为潜在肝动脉栓塞剂的合成与评估

获取原文
获取原文并翻译 | 示例
           

摘要

Transcatheter arterial chemoembolization (TACE) is well known as an effective treatment for hepatocellular carcinoma (HCC). In the present study, a novel embolic agent of sodium alginate (SA)-modified silk fibroin (SF) microspheres was successfully prepared by emulsifying cross-linking method. The SA-modified SF microspheres were evaluated for the ability of embolization by investigating the morphology, particle size, swelling ratio, degradation, cytotoxicity, blood compatibility, and in vivo embolization. The results found that SA-modified SF microspheres had smooth surfaces and good sphericity. Swelling ratio of the microspheres can meet the requirements of arterial embolic agent and have pH and temperature sensitivity. Furthermore, hemolytic and anticoagulant studies have proved that the microspheres have good blood compatibility. Cytotoxicity tests indicated that the microspheres could promote the proliferation of fibroblasts and HUVEC. In vivo embolization evaluation of microspheres revealed that the arteries could be embolized by SA-modified SF microspheres in 3 weeks. The ability of drug loading and releasing of microspheres was proved by the controlled release profile of Adriamycin hydrochloride. The findings indicated that the SA-modified SF microspheres can be used as a potentially biodegradable arterial embolic agent for liver cancer therapy. (C) 2019 Elsevier B.V. All rights reserved.
机译:经导管动脉化疗栓塞(TACE)是众所周知的肝细胞癌(HCC)的有效治疗方法。在本研究中,通过乳化交联方法成功地制备了藻酸钠(SA)制备的藻酸钠(SA)胺化丝素蛋白(SF)微球的新型栓塞剂。通过研究形态,粒度,溶胀比,降解,细胞毒性,血液相容性和体内栓塞来评估栓塞能力的SA改性的SF微球。结果发现SA改性的SF微球具有光滑的表面和良好的球形。微球的溶胀比可以满足动脉栓塞剂的要求并具有pH和温度敏感性。此外,溶血和抗凝剂研究证明了微球具有良好的血液相容性。细胞毒性试验表明,微球可以促进成纤维细胞和HUVEC的增殖。在微球的体内栓塞评估显示,动脉可以在3周内通过SA改性的SF微球栓塞。通过盐酸亚霉素的控释曲线证明了微球的药物载荷和释放能力。结果表明,SA改性的SF微球可用作肝癌疗法的潜在可生物降解的动脉栓塞剂。 (c)2019 Elsevier B.v.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号